Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2019

View Archived Issues

Neurotransmitter receptor stimulates early blood cell progenitors

Presentation of phase I results of PEN-866 in patients with advanced solid tumors

Knockdown of Fas death receptor shows hepatoprotective effect against NASH in mice

Novel PDE-delta inhibitor disrupts its interaction with mutant KRAS and inhibits tumor growth

BETonMACE phase III epigenetics study does not meet primary endpoint

Cabaletta Bio receives FDA IND clearance to initiate first-in-human study of DSG3-CAART

FDA clears IND for rapid personalized manufacture of CD19-specific CAR-T

TLC initiates phase III pivotal EXCELLENCE study of TLC-599

Preclinical and early clinical data for BBT-877 reported

Fluzoparib shows promising antitumor activity in advanced BRCA1/2-mutated ovarian cancer

Phase II data presented for ampreloxetine as treatment of neurogenic orthostatic hypotension

RELIEF study supports use of pirfenidone in non-IPF lung fibrosis

PharmaBlock Sciences patents PRMT5 inhibitors

Fujian Haixi Pharmaceuticals presents new CSF-1R inhibitors

Sunshine Lake Pharma identifies new PD-1/PD-L1 interaction inhibitors

Agenus patents anti-CD73 antibodies for cancer

Lundbeck discloses antibodies targeting tau

Phase II study of NCX-470 in open-angle glaucoma or ocular hypertension meets primary endpoint

Equillium initiates phase Ib study of itolizumab in lupus nephritis

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Checkmate's CMP-001 studied in combinations with Bavencio for SCCHN

IL-11 identified as therapeutic target in pulmonary fibrosis

New registrational study evaluates miransertib in Proteus syndrome and PROS

ContraFect plans single phase III study of exebacase for S. aureus bacteremia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...